Medical Editor: John P. Cunha, DO, FACOEP
Afeditab CR (nifedipine extended-release tablets) is an extended release calcium channel blocker indicated for the treatment of hypertension. Afeditab CR may be used alone or in combination with other antihypertensive agents. Common side effects of Afeditab CR include headache, flushing (warmth, redness, tingly feeling), dizziness, fatigue, weakness, nausea, or constipation.
Dosage of Afeditab CR is adjusted according to each patient's needs. The general starting dose of Afeditab CR is 30 mg once daily. Afeditab CR may interact with beta-adrenergic blocking agents, antiarrhythmics, flecainide, other calcium channel blockers, verapamil, ACE inhibitors, angiotensin-II blockers, candesartan, beta-blockers, timolol, central alpha1-blockers, digitalis, antithrombotics, platelet aggregation inhibitors, antifungals, antisecretory drugs, antibacterials, antitubercular drugs, antivirals, CNS drugs, antiemetics, immunosuppressive drugs, glucose lowering drugs, grapefruit juice, and St. John's Wort. Tell your doctor all medications and supplements you use. During pregnancy, Afeditab CR should only be taken if prescribed. Tell your doctor if you are pregnant or become pregnant before taking Afeditab CR. Afeditab CR passes into breast milk. Breastfeeding while taking Afeditab CR is not recommended.
Our Afeditab CR (nifedipine extended-release tablets) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The incidence of adverse events during treatment with nifedipine extended-release tablets in doses up to 90 mg daily were derived from multi-center placebo-controlled clinical trials in 370 hypertensive patients. Atenolol 50 mg once daily was used concomitantly in 187 of the 370 patients on nifedipine extended-release tablets and in 64 of the 126 patients on placebo. All adverse events reported during nifedipine extended-release tablets therapy were tabulated independently of their causal relationship to medication.
The most common adverse event reported with nifedipine extended-release tablets was peripheral edema. This was dose related and the frequency was 18% on nifedipine extended-release tablets 30 mg daily, 22% on nifedipine extended-release tablets 60 mg daily and 29% on nifedipine extended-release tablets 90 mg daily versus 10% on placebo.
Other common adverse events reported in the above placebo-controlled trials include:
|Adverse Event||NIFEDIPINE EXTENDED-RELEASE TABLETS(%)
Where the frequency of adverse events with nifedipine extended-release tablets and placebo is similar, causal relationship cannot be established.
The following adverse events were reported with an incidence of 3% or less in daily doses up to 90 mg:
Body as a Whole/Systemic: chest pain, leg pain
Musculoskeletal: leg cramps
Urogenital: impotence, urinary frequency
Other adverse events reported with an incidence of less than 1.0% were:
Gastrointestinal: abdominal pain, diarrhea, dry mouth, dysphagia, dyspepsia, eructation, esophagitis, flatulence, gastrointestinal disorder, gastrointestinal hemorrhage, GGT increased, gum disorder, gum hemorrhage, vomiting
Metabolic: gout, weight loss
The following adverse events have been reported rarely in patients given nifedipine in coat core or other formulations: allergenic hepatitis, alopecia, anaphylactic reaction, anemia, arthritis with ANA (+), depression, erythromelalgia, exfoliative dermatitis, fever, gingival hyperplasia, gynecomastia, hyperglycemia, jaundice, leukopenia, mood changes, muscle cramps, nervousness, paranoid syndrome, purpura, shakiness, sleep disturbances, Stevens-Johnson syndrome, syncope, taste perversion, thrombocytopenia, toxic epidermal necrolysis, transient blindness at the peak of plasma level, tremor and urticaria.
Read the entire FDA prescribing information for Afeditab CR (Nifedipine Extended-Release Tablets)